Sanaria
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2003 |
| Founder | Stephen L. Hoffman |
| Headquarters | Rockville, Maryland , United States |
| Products | Whole-parasite vaccines targeting malaria, monoclonal antibodies against malaria, vaccines for diarrheal diseases, immunotherapeutics for hepatic conditions |
| Website | www |
Sanaria is a biotechnology firm specializing in the development of whole-parasite vaccines targeting malaria. Its product range encompasses monoclonal antibodies against malaria, vaccines aimed at diarrheal diseases, and immunotherapeutics for hepatic conditions. Sanaria’s vaccines employ the sporozoite (SPZ) phase of the malaria parasite, Plasmodium, serving both as an immunogen and a vehicle for delivering immunomodulatory agents.
Mission statement
Sanaria is dedicated to creating and commercializing whole-parasite PfSPZ vaccines that offer sustained, high-level immunity against Plasmodium falciparum, the species accountable for more than 95% of severe malaria worldwide and noted for its drug resistance. The company’s long-range business plan prioritizes vaccines designed to prevent all forms of human malaria, focusing on populations in endemic regions such as pregnant women, children, and travelers, with the goal of interrupting transmission and achieving disease eradication.
History
Established in 2003 by entrepreneur Stephen L. Hoffman, Sanaria began its operations in Rockville, Maryland, initially funded through a phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID). Additional financial support included a $4.09 million grant from the U.S. Army Medical Research program to propel vaccine development efforts. In 2007, a $29.3 million award from the Bill and Melinda Gates Foundation via PATH’s Malaria Vaccine Initiative enabled construction of Sanaria’s manufacturing facility.
In 2009, the FDA authorized Sanaria to commence human trials for its PfSPZ Vaccine, which has shown robust protection against controlled human malaria infection (CHMI) and natural exposure in Africa lasting up to two years without booster immunizations, including during pregnancy. The vaccine received FDA Fast Track status in 2016, highlighting its significant market potential.
Sanaria’s next-generation PfSPZ-CVac (CQ) vaccine demonstrated improved efficacy at much lower dosages. The newest candidate, PfSPZ-LARC2 Vaccine, is planned to enter clinical testing in late 2024 across sites in the US, Germany, and Burkina Faso. It aims to preserve the safety profile of preceding vaccines while enhancing its potency and effectiveness.
This well-structured development pipeline exemplifies Sanaria’s dedication to expanding its global footprint and increasing market presence in malaria prevention through innovative whole-parasite vaccine platforms.
Clinical trials
A total of twenty-two clinical trials involving PfSPZ Vaccine (radiation-attenuated SPZ) have been completed or are underway across the US, Europe, and African countries including Tanzania, Kenya, Mali, Burkina Faso, Gabon, and Equatorial Guinea. A recent investigation involving Malian women of reproductive age revealed significant vaccine efficacy (VE) against malaria infection and clinical cases over an 18-month period, ranging between 41% and 86% without booster shots. Numerous participants became pregnant during follow-up; VE during pregnancy was recorded at 57% over two years—marking the first documented vaccine-induced protection against pregnancy-associated malaria. The vaccine's safety was comparable to placebo across thirteen randomized studies. Building on these findings, a new trial scheduled for 2025 will evaluate safety and efficacy in pregnant Malian women during their second or third trimester. This effort is a collaboration among the Malaria Research and Training Center at the University of Bamako, NIAID’s Laboratory of Malaria Immunology and Vaccinology, and Sanaria.
Eleven clinical trials evaluating PfSPZ-CVac (chemo-attenuated SPZ) have been conducted in locations including the Netherlands, US, Germany, Equatorial Guinea, Mali, and Indonesia. Two Phase I studies published in Nature (2021) reported 100% protection against heterologous malaria challenge three months after immunization—the highest efficacy documented for a malaria vaccine to date.
Sanaria is preparing first-in-human studies for PfSPZ-LARC2 Vaccine—a genetically attenuated parasite exhibiting late-arrest with dual gene deletions—designed to match or exceed PfSPZ-CVac's effectiveness while maintaining the safety profile of PfSPZ Vaccine. This candidate was developed jointly with Seattle Children's Research Institute and builds upon experience from Sanaria’s earlier genetically modified PfSPZ-GA1 vaccine (single gene deletion), which was safe but did not outperform PfSPZ Vaccine and has since been discontinued. Clinical trials for PfSPZ-LARC2 are planned for 2024-25 in Seattle, Tübingen (Germany), and Burkina Faso.
Sanaria’s non-attenuated infectious sporozoites—branded as Sanaria PfSPZ Challenge—are widely used as essential research tools globally. Employed as the immunogen in PfSPZ-CVac and to infect volunteers during controlled human malaria infection (CHMI) studies, PfSPZ Challenge facilitates assessment of vaccine and drug efficacy alongside immune response analyses across diverse populations. CHMI trials using PfSPZ Challenge have been performed worldwide—including sites in the US, Europe, and multiple African nations—supporting numerous academic dissertations. Sanaria provides two variants of PfSPZ Challenge (West African and Brazilian strains) with plans to develop additional strains to broaden global research applications.
I-PfSPZ-C
Sanaria's research and development efforts are coordinated through the International PfSPZ Consortium (I-PfSPZ-C), which includes approximately 290 researchers and funding partners from 86 institutions spanning 28 countries. This consortium is dedicated to creating whole PfSPZ malaria vaccines designed to prevent malaria and support its targeted regional eradication. Members of the consortium meet once or twice yearly to evaluate data, exchange knowledge, and strategize upcoming research initiatives.
Funding
The advancement of Sanaria's PfSPZ vaccines is financed by principal supporters such as the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the U.S. Department of Defense (DoD), the Bill & Melinda Gates Foundation, and the Government of Equatorial Guinea. Contributions also come from corporate social responsibility programs of U.S.-based energy firms including Marathon Oil, Noble Energy, and AMPCO. Additional funding sources include Top Institute Pharma in the Netherlands, universities located in Nijmegen and Leiden, the University of Tübingen, the German Centre for Infection Research (DZIF), the Swiss Tropical Public Health Institute, the Swiss Government, and the Tanzania Commission on Science and Technology.
In 2020, Sanaria was awarded €12.9 million by the European Union Malaria Fund (EUMF) to further develop two malaria vaccine candidates, a malaria preventive treatment, and a vaccine targeting SARS-CoV-2.